Skip to main content
. 2021 May 27;12:684344. doi: 10.3389/fimmu.2021.684344

Figure 5.

Figure 5

Pretreatment of sorafenib decreases LPS-mediated AKT and STAT3 phosphorylation in wild-type mice. (A, C) Immunofluorescence staining with anti-p-AKTS473 and anti-p- STAT3S727 antibody of brain slices from wild-type mice treated with sorafenib followed by LPS. (B, D) Quantification of the data in (A, C) (analyzed number of brain slices/images (n); p-AKT S473: Vehicle, n =16; LPS, n=16; Sorafenib + LPS, n=14, p-STAT3 S727, Vehicle, n=23; LPS, n=22; Sorafenib + LPS, n=20). *p < 0.05, **p < 0.01, Scale bar = 200 μM.